NeoGenomics to present RaDaR ST bridging study at ISLB 2025

NeoGenomics (NEO) will present new research at the International Society of Liquid Biopsy Annual Congress 2025 demonstrating high concordance between its RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease in solid tumors. NeoGenomics will also present on the progress of its NextGen MRD research program, as well as three additional posters highlighting the company’s work in liquid biopsy and genomic profiling across solid tumor types, the company announced. The bridging study, “Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types”, evaluated matched samples from 166 patients representing 15 solid tumor types. RaDaR ST demonstrated 97% concordance and maintained equivalent sensitivity with RaDaR 1.0. This study provides analytical confirmation that RaDaR ST maintains the performance of RaDaR 1.0, supporting continuity in MRD assessment as the platform is updated. RaDaR ST is currently covered by Medicare for HR+/HER2- breast cancer and HPV- head and neck carcinoma and has demonstrated utility across multiple tumor types. “MRD has become an important part of a patient’s journey for cancer surveillance and monitoring. This study shows that RaDaR ST delivers equivalent sensitivity as compared to RaDaR 1.0. We are excited to offer clinicians and patients MRD testing optionality with the expected launch of RaDaR ST in Q1 2026. As we continue to invest in novel MRD technologies for the future, the expanding portfolio of MRD solutions will help address unmet needs for sensitive and accurate residual disease detection and monitoring in patients with cancer,” said Tony Zook, CEO.